...
aciu-img

AC Immune Ltd, Common Stock

ACIU

NMQ

$3.125

-$0.02

(-0.64%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$311.67M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
19.61K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.28
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.25 L
$5.14 H
$3.125

About AC Immune Ltd, Common Stock

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameACIUSectorS&P500
1-Week Return-2.18%-1.66%0.16%
1-Month Return-0.95%-3.08%1%
3-Month Return2.95%-6.66%10.69%
6-Month Return-30.38%-1.54%12.9%
1-Year Return-18.65%8.85%30.94%
3-Year Return-38.91%7.9%29.66%
5-Year Return-63.78%45.12%92.82%
10-Year Return-79.95%104.55%193.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue111.03M15.43M944.00K3.94M14.80M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":13.9,"profit":true},{"date":"2021-12-31","value":0.85,"profit":true},{"date":"2022-12-31","value":3.54,"profit":true},{"date":"2023-12-31","value":13.33,"profit":true}]
Cost of Revenue50.43M59.49M62.28M60.34M54.61M[{"date":"2019-12-31","value":80.97,"profit":true},{"date":"2020-12-31","value":95.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":96.88,"profit":true},{"date":"2023-12-31","value":87.68,"profit":true}]
Gross Profit60.59M(44.06M)(62.28M)(56.40M)(39.80M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-72.71,"profit":false},{"date":"2021-12-31","value":-102.79,"profit":false},{"date":"2022-12-31","value":-93.08,"profit":false},{"date":"2023-12-31","value":-65.69,"profit":false}]
Gross Margin54.58%(285.50%)(6597.67%)(1433.32%)(268.93%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-523.13,"profit":false},{"date":"2021-12-31","value":-12088.87,"profit":false},{"date":"2022-12-31","value":-2626.26,"profit":false},{"date":"2023-12-31","value":-492.77,"profit":false}]
Operating Expenses66.49M76.69M79.01M74.78M13.82M[{"date":"2019-12-31","value":84.15,"profit":true},{"date":"2020-12-31","value":97.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":94.65,"profit":true},{"date":"2023-12-31","value":17.49,"profit":true}]
Operating Income44.54M(61.26M)(79.01M)(70.85M)(53.62M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-137.55,"profit":false},{"date":"2021-12-31","value":-177.41,"profit":false},{"date":"2022-12-31","value":-159.08,"profit":false},{"date":"2023-12-31","value":-120.41,"profit":false}]
Total Non-Operating Income/Expense(717.00K)(767.00K)11.92M(179.00K)269.00K[{"date":"2019-12-31","value":-6.01,"profit":false},{"date":"2020-12-31","value":-6.43,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-1.5,"profit":false},{"date":"2023-12-31","value":2.26,"profit":true}]
Pre-Tax Income45.44M(61.92M)(72.99M)(70.74M)(54.22M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-136.26,"profit":false},{"date":"2021-12-31","value":-160.63,"profit":false},{"date":"2022-12-31","value":-155.67,"profit":false},{"date":"2023-12-31","value":-119.32,"profit":false}]
Income Taxes1.89M184.00K3.00K13.00K10.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":9.71,"profit":true},{"date":"2021-12-31","value":0.16,"profit":true},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":0.53,"profit":true}]
Income After Taxes43.55M(62.10M)(73.00M)(70.75M)(54.23M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-142.61,"profit":false},{"date":"2021-12-31","value":-167.62,"profit":false},{"date":"2022-12-31","value":-162.47,"profit":false},{"date":"2023-12-31","value":-124.54,"profit":false}]
Income From Continuous Operations45.44M(61.92M)(73.00M)(70.75M)(54.23M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-136.26,"profit":false},{"date":"2021-12-31","value":-160.64,"profit":false},{"date":"2022-12-31","value":-155.7,"profit":false},{"date":"2023-12-31","value":-119.35,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income45.44M(62.10M)(73.00M)(70.75M)(54.23M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-136.67,"profit":false},{"date":"2021-12-31","value":-160.64,"profit":false},{"date":"2022-12-31","value":-155.7,"profit":false},{"date":"2023-12-31","value":-119.35,"profit":false}]
EPS (Diluted)0.69(0.84)(0.99)(0.85)(0.64)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-121.74,"profit":false},{"date":"2021-12-31","value":-143.48,"profit":false},{"date":"2022-12-31","value":-123.19,"profit":false},{"date":"2023-12-31","value":-92.75,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACIU
Cash Ratio 1.56
Current Ratio 1.86

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACIU
ROA (LTM) -12.04%
ROE (LTM) -31.16%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACIU
Debt Ratio Lower is generally better. Negative is bad. 0.47
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.53

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACIU
Trailing PE NM
Forward PE 7.68
P/S (TTM) 7.61
P/B 2.10
Price/FCF NM
EV/R 2.90
EV/Ebitda NM
PEG NM

FAQs

What is AC Immune Ltd share price today?

AC Immune Ltd (ACIU) share price today is $3.125

Can Indians buy AC Immune Ltd shares?

Yes, Indians can buy shares of AC Immune Ltd (ACIU) on Vested. To buy AC Immune Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACIU stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of AC Immune Ltd be purchased?

Yes, you can purchase fractional shares of AC Immune Ltd (ACIU) via the Vested app. You can start investing in AC Immune Ltd (ACIU) with a minimum investment of $1.

How to invest in AC Immune Ltd shares from India?

You can invest in shares of AC Immune Ltd (ACIU) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACIU stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in AC Immune Ltd shares
What is AC Immune Ltd 52-week high and low stock price?

The 52-week high price of AC Immune Ltd (ACIU) is $5.14. The 52-week low price of AC Immune Ltd (ACIU) is $2.25.

What is AC Immune Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of AC Immune Ltd (ACIU) is

What is AC Immune Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of AC Immune Ltd (ACIU) is 2.10

What is AC Immune Ltd dividend yield?

The dividend yield of AC Immune Ltd (ACIU) is 0.00%

What is the Market Cap of AC Immune Ltd?

The market capitalization of AC Immune Ltd (ACIU) is $311.67M

What is AC Immune Ltd’s stock symbol?

The stock symbol (or ticker) of AC Immune Ltd is ACIU

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top